Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$3.70 -0.8%	$3.54	$2.28 ▼ $6.96	$30.84M	0.55	88,832 shs	32,816 shs
LTRN Lantern Pharma	$3.76 -5.8%	$3.38	$2.55 ▼ $6.12	$43.03M	1.54	81,606 shs	370,221 shs
LVTX LAVA Therapeutics	$1.40 -5.4%	$1.31	$0.85 ▼ $2.39	$38.93M	0.48	152,581 shs	29,082 shs
NLSP NLS Pharmaceutics	$2.20 +3.3%	$2.17	$1.30 ▼ $15.59	$7.66M	0.18	848,244 shs	145,551 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	-0.80%	-2.63%	-9.76%	+22.52%	-26.00%
LTRN Lantern Pharma	-5.76%	+6.21%	+23.28%	+7.74%	-13.56%
LVTX LAVA Therapeutics	-5.41%	+3.18%	+6.87%	+13.82%	-22.22%
NLSP NLS Pharmaceutics	+3.29%	-5.17%	-3.51%	+53.85%	+973.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLNN Clene	3.5681 of 5 stars	3.6	5.0	0.0	0.0	2.7	2.5	0.6
LTRN Lantern Pharma	2.9889 of 5 stars	3.5	5.0	0.0	0.0	2.3	0.8	0.6
LVTX LAVA Therapeutics	2.197 of 5 stars	3.0	5.0	0.0	0.0	3.3	0.0	0.0
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLNN Clene	3.17	Buy	$40.00	981.08% Upside
LTRN Lantern Pharma	3.00	Buy	$25.00	564.89% Upside
LVTX LAVA Therapeutics	2.00	Hold	$3.17	126.19% Upside
NLSP NLS Pharmaceutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NLSP, LTRN, CLNN, and LVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/8/2025	CLNN Clene	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $33.00
5/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/23/2025	CLNN Clene	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLNN Clene	$340K	90.00	N/A	N/A	($1.06) per share	-3.49
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$1.96 per share	N/A
LVTX LAVA Therapeutics	$11.98M	3.07	N/A	N/A	$1.06 per share	1.32
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	($0.37) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLNN Clene	-$39.40M	-$4.04	N/A	N/A	N/A	-8,306.00%	N/A	-105.11%	8/6/2025 (Estimated)
LTRN Lantern Pharma	-$20.78M	-$1.84	N/A	N/A	N/A	N/A	-83.26%	-70.65%	8/6/2025 (Estimated)
LVTX LAVA Therapeutics	-$25.11M	-$1.04	N/A	N/A	N/A	N/A	-86.38%	-34.12%	8/19/2025 (Estimated)
NLSP NLS Pharmaceutics	-$1.98M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/15/2025 (Estimated)

Latest NLSP, LTRN, CLNN, and LVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	CLNN Clene	-$0.49	N/A	N/A	N/A	$0.06 million	N/A
5/15/2025	Q1 2025	LTRN Lantern Pharma	-$0.49	-$0.42	+$0.07	-$0.42	N/A	N/A
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A
5/7/2025	Q1 2025	CLNN Clene	-$1.10	-$0.50	+$0.60	-$0.09	$0.07 million	$0.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLNN Clene	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLNN Clene	N/A	1.36	1.36
LTRN Lantern Pharma	N/A	4.86	4.86
LVTX LAVA Therapeutics	N/A	6.73	6.73
NLSP NLS Pharmaceutics	N/A	2.69	2.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLNN Clene	23.28%
LTRN Lantern Pharma	28.62%
LVTX LAVA Therapeutics	N/A
NLSP NLS Pharmaceutics	N/A

Insider Ownership

Company	Insider Ownership
CLNN Clene	35.30%
LTRN Lantern Pharma	7.31%
LVTX LAVA Therapeutics	9.50%
NLSP NLS Pharmaceutics	16.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLNN Clene	100	8.27 million	5.35 million	Optionable
LTRN Lantern Pharma	20	10.78 million	10.00 million	Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
NLSP NLS Pharmaceutics	6	3.60 million	3.01 million	Not Optionable

NLSP, LTRN, CLNN, and LVTX Headlines

Recent News About These Companies

NLS Pharmaceutics (NASDAQ:NLSP) Upgraded at Wall Street Zen

July 6, 2025 | americanbankingnews.com

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

June 30, 2025 | prnewswire.com

NLS Pharmaceutics Ltd.: NLS Pharmaceutics CEO Issues Letter to Shareholders

June 18, 2025 | finanznachrichten.de

NLS Pharmaceutics CEO Issues Letter to Shareholders

June 16, 2025 | prnewswire.com

NLS Pharmaceutics to present Mazindol study at ASCP Meeting

May 22, 2025 | investing.com

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

May 21, 2025 | prnewswire.com

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

April 15, 2025 | prnewswire.com

NLS Pharmaceutics, Kadimastem announce up to $3M equity financing

April 1, 2025 | markets.businessinsider.com

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

March 31, 2025 | accessnewswire.comA

NLS Pharmaceutics CEO Issues Letter to Shareholders

March 10, 2025 | prnewswire.com

NLS Pharmaceutics announces new preclinical data for AEX-2

February 27, 2025 | markets.businessinsider.com

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

February 27, 2025 | prnewswire.com

NLS Pharmaceutics and Kadimastem complete pre-IND diabetes meeting with FDA

February 25, 2025 | markets.businessinsider.com

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

February 25, 2025 | prnewswire.com

NLS Pharmaceutics files $75M mixed securities shelf

February 11, 2025 | markets.businessinsider.com

NLS and Kadimastem to merge, aim for diabetes care innovation

February 10, 2025 | msn.com

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

February 10, 2025 | prnewswire.com

NLS Pharmaceutics files to sell 645,161 common shares for holders

February 5, 2025 | markets.businessinsider.com

NLS Pharmaceutics AG (NLSP) Stock: Analyzing Its Quiet Power

February 3, 2025 | bovnews.comB

Kadimastem Ltd.: Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

January 31, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLSP, LTRN, CLNN, and LVTX Company Descriptions

Clene NASDAQ:CLNN

$3.70 -0.03 (-0.80%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$3.70 0.00 (0.00%)

As of 04:00 AM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Lantern Pharma NASDAQ:LTRN

$3.76 -0.23 (-5.76%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$3.83 +0.07 (+1.76%)

As of 04:02 AM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

LAVA Therapeutics NASDAQ:LVTX

$1.40 -0.08 (-5.41%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$1.38 -0.02 (-1.43%)

As of 07:00 AM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

NLS Pharmaceutics NASDAQ:NLSP

$2.20 +0.07 (+3.29%)

Closing price 07/15/2025 03:59 PM Eastern

Extended Trading

$2.22 +0.02 (+0.91%)

As of 07/15/2025 07:54 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time